Moleculin Biotech raises $6M from immediate exercise of warrants.

Moleculin Biotech has entered into agreements with certain holders of its existing warrants to exercise up to 16.2 million shares of common stock at $0.37 per share. The total gross proceeds from the exercise are expected to be approximately $6 million, with Roth Capital Partners acting as the Company's financial advisor. The shares are registered pursuant to an effective registration statement on Form S-1.

Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing treatments for tumors and viruses, has secured $6.0 million in gross proceeds through a strategic warrant exercise agreement with existing warrant holders. The company entered into agreements to exercise up to 16,216,216 shares of common stock at $0.37 per share, providing immediate liquidity for its operations.

In exchange for the immediate exercise, Moleculin will issue new unregistered warrants for up to 64,864,864 shares at an exercise price of $0.55 per share. These new warrants are exercisable upon shareholder approval and have a term of five years. The transaction is expected to close on August 28, 2025 [1].

Roth Capital Partners is acting as the Company's financial advisor for this transaction. The company plans to use the proceeds for working capital and general corporate purposes. This financing mechanism accomplishes several objectives simultaneously, providing immediate capital while potentially setting up additional future financing at a higher price point [2].

The involvement of Roth Capital Partners suggests institutional support for the transaction structure. Moleculin's decision to pursue this warrant exercise rather than other financing options likely indicates management's preference for working with existing investors while minimizing immediate dilution impact compared to alternatives like a direct offering at current market prices.

Moleculin Biotech's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and lack cardiotoxicity common with currently prescribed anthracyclines. The company is also developing WP1066, an Immune/Transcription Modulator, and a portfolio of antimetabolites for treating various cancers and viruses.

This strategic financing move is a significant step for Moleculin as it advances its portfolio targeting hard-to-treat tumors and viruses. The $6 million infusion strengthens the company's balance sheet and supports its ongoing research and development efforts.

References:
[1] https://www.stocktitan.net/news/MBRX/moleculin-announces-exercise-of-warrants-for-6-0-million-gross-uuk8e2f3g8hv.html
[2] https://www.globenewswire.com/news-release/2025/08/28/3140796/0/en/Moleculin-Announces-Exercise-of-Warrants-for-6-0-Million-Gross-Proceeds.html